707 related articles for article (PubMed ID: 27012405)
1. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
[TBL] [Abstract][Full Text] [Related]
3. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
[TBL] [Abstract][Full Text] [Related]
4. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
5. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
6. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
[TBL] [Abstract][Full Text] [Related]
8. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
9. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
12. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.
El-Oumeiri B; Mc Entee K; Annoni F; Herpain A; Vanden Eynden F; Jespers P; Van Nooten G; van de Borne P
BMC Cardiovasc Disord; 2018 May; 18(1):99. PubMed ID: 29783950
[TBL] [Abstract][Full Text] [Related]
14. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.
Felker GM; Solomon SD; McMurray JJV; Cleland JGF; Abbasi SA; Malik FI; Zhang H; Globe G; Teerlink JR;
Circ Heart Fail; 2020 Dec; 13(12):e007814. PubMed ID: 33176437
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
Felker GM; Solomon SD; Metra M; Mcmurray JJV; Diaz R; Claggett B; Lanfear DE; Vandekerckhove H; Biering-Sørensen T; Lopes RD; Arias-Mendoza A; Momomura SI; Corbalan R; Ramires FJA; Zannad F; Heitner SB; Divanji PH; Kupfer S; Malik FI; Teerlink JR
J Card Fail; 2024 Jun; 30(6):755-763. PubMed ID: 38215932
[TBL] [Abstract][Full Text] [Related]
16. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
[TBL] [Abstract][Full Text] [Related]
18. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
McMurray JJV; Ponikowski P; Bolli GB; Lukashevich V; Kozlovski P; Kothny W; Lewsey JD; Krum H;
JACC Heart Fail; 2018 Jan; 6(1):8-17. PubMed ID: 29032139
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
20. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.
Patel PH; Nguyen M; Rodriguez R; Surani S; Udeani G
Cureus; 2021 Jan; 13(1):e12419. PubMed ID: 33542867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
